Introduction {#section1-1533033820916505}
============

Stereotactic body radiation therapy (SBRT) involves the delivery of a single high dose radiation treatment or few fractionated radiation treatments, which showed high local control in tumors.^[@bibr1-1533033820916505],[@bibr2-1533033820916505]^ According to the International Commission Radiological Units (ICRU) report, the concept of the planning target volume (PTV) is commonly used to account for tumor motion and setup uncertainty.^[@bibr3-1533033820916505]^ The internal target volume (ITV) is technically the motion envelope encompassing the clinical target volume (CTV).^[@bibr3-1533033820916505],[@bibr4-1533033820916505]^

However, the optimal margin for the setup uncertainty from ITV to PTV is controversial, as it can be reduced by updating the image-guided radiation therapy (IGRT) equipment. Cristina Garibaldi *et al* ^[@bibr5-1533033820916505]^ found that setup uncertainties could be brought down to about 3 mm, in all directions, using a cone-beam computed tomography (CT). Richmond *et al* ^[@bibr6-1533033820916505]^ recommended an ITV expansion margin of 4 mm, in all directions, to compensate for residual setup uncertainties in image-guidance and intrafraction motion for patients immobilized in a body-fix device. Therefore, a conventional SBRT plan optimized with a 5-mm uniform margin PTV on the ITV may unnecessarily increase the volume of the irradiated normal tissue (NT). An additional problem is that the PTV concept as typically applied in intensity modulated radiotherapy (IMRT) planning relies on the so-called static dose cloud approximation. The underlying assumption is that the dose distribution in the treatment room coordinates is not affected by changes in the patient's anatomy. That is, it is assumed that the CTV receives the prescribed dose if it stays within the PTV. This fundamental assumption is not generally fulfilled and is violated.

Various efforts have been made by previous studies to reduce the PTV margin. Li *et al* ^[@bibr7-1533033820916505]^ proposed a true 4-dimensional planning method (t4Dplan) on IMRT using 4-dimensional computed tomography (4DCT) data sets to maximize the sparing of critical structures. The rationale of the t4Dplan method is to deliver a smaller dose to the tumor when the tumor is at its T0 position and deliver higher doses when it is close to its T50 position. This will compensate for the under dosing at the T0 position, given that patients spend more time in the T50 phase than in the T0 phase during the entire respiratory cycle. Their studies indicate that the t4Dplan method does not need a target margin, which improves the sparing of normal structures. Suh *et al* ^[@bibr8-1533033820916505]^ developed a 4-dimensional (4D)-IMRT treatment planning method by modifying and applying a dynamic multileaf collimator motion-tracking algorithm. A 4D treatment plan was created based on a 4DCT image that was flexible enough to account for changes in patient setup during the treatment. These gating and tracking strategies were effective in reducing the volume of the irradiated target; however, they resulted in markedly extended treatment times and could not be widely used in clinical practice.

Recently, a new strategy to deal with the setup uncertainty, that uses a robust optimization algorithm instead of PTV margin-based optimization, has been reported to be effective in compensating for the setup uncertainty in treatment planning. Zhang *et al* ^[@bibr9-1533033820916505]^ evaluated CTV-based robust optimization for lung cancer, and the results demonstrated that a robust optimization can generate plans that offer increased sparing of organ at risk (OAR); especially, for normal lung tissue and OARs near the target. Liang *et al* ^[@bibr10-1533033820916505]^ evaluated ITV-based robust optimization (RO-ITV) for lung cancer with SBRT planning and showed that it can account for setup uncertainties.

In our study, we extended the RO-ITV technique to SBRT planning by accounting for plan quality and plan robustness. Innovation is mainly carried out from the following 2 aspects: On one hand, the plan quality considers more details that are of clinical concern, such as dose falloff product (DFP) for dose sharpness and the normal tissue complication probability (NTCP) model for radiation pneumonitis (RP). On the other, we developed a new metric, which is the dose--volume histogram band width (DVHBW), as an independent parameter (or dosimetric endpoint) to quantitatively assess the robustness of the plan, and whether its robustness is affected by updating the IGRT equipment. The proposed DVHBW method provides a simple metric to compare the robustness of different SBRT plans with statistical evaluation.

Materials and Methods {#section2-1533033820916505}
=====================

Patient and Plan Data Characteristics {#section3-1533033820916505}
-------------------------------------

A total of 50 patients with early stage (IA/IB) non-small cell lung cancer (NSCLC) were treated with SBRT and retrospectively selected for this study, which was approved by the local institutional research review board. Gross target volumes (GTVs) were contoured by the attending radiation oncologists, on each phase of the 4DCT, and ITVs were created by encompassing the extent of 10 GTV motion in all 10 phases of 4DCT. The ITV was expanded with the setup uncertainty from the PTV by including a setup uncertainty of 5 mm in the superior--inferior, anterior--posterior (AP), and left--right (LR) directions.^[@bibr11-1533033820916505]^ The median ITV volume was 19.94 cm^3^ (range of 0.92-70.82 cm^3^) and the median PTV volume was 47.56 cm^3^ (range of 5.87-133.20 cm^3^).

All clinical SBRT plans used the VMAT (RapidArc) technique with the Edge linear accelerator (Linac; Varian Medical Systems, Palo Alto, California) and a 120-leaf multileaf collimation (MLC) flattening filter free mode (6 MV and 1200 MU/min dose rate). The treatment plans were created in the Eclipse TPS version11 (Varian Medical Systems) with the prescription dose of 50 Gy in 4 fractions. A summary of the patients' information is listed in [Table 1](#table1-1533033820916505){ref-type="table"}. The dose prescription was 50 Gy in 4 fractions, that is, 12.5 Gy per fraction.

###### 

Patient and Peripheral NSCLC Characters (Tumor Size, Prescription).

![](10.1177_1533033820916505-table1)

  Patient No.      Tumor Stage   ITV, cm^3^           PTV, cm^3^            Prescription Dose, Gy
  ---------------- ------------- -------------------- --------------------- -----------------------
  1                IA            23.44                47.05                 12.5 Gy × 4fx
  2                IA            7.77                 24.83                 12.5 Gy × 4fx
  3                IB            34.63                94.12                 12.5 Gy × 4fx
  4                IA            4.18                 17.79                 12.5 Gy × 4fx
  5                IA            4.26                 15.14                 12.5 Gy × 4fx
  6                IB            27.11                84.12                 12.5 Gy × 4fx
  7                IB            37.35                85.54                 12.5 Gy × 4fx
  8                IA            4.81                 19.16                 12.5 Gy × 4fx
  9                IA            7.71                 24.76                 12.5 Gy × 4fx
  10               IB            27.36                48.06                 12.5 Gy × 4fx
  11               IB            47.55                91.28                 12.5 Gy × 4fx
  12               IA            0.92                 5.87                  12.5 Gy × 4fx
  13               IB            13.97                38.01                 12.5 Gy × 4fx
  14               IB            70.82                133.2                 12.5 Gy × 4fx
  15               IB            36.49                82.26                 12.5 Gy × 4fx
  16               IB            35.43                71.59                 12.5 Gy × 4fx
  17               IB            29.23                51.25                 12.5 Gy × 4fx
  18               IB            33.33                87.26                 12.5 Gy × 4fx
  19               IA            9.52                 28.62                 12.5 Gy × 4fx
  20               IB            26.66                63.35                 12.5 Gy × 4fx
  21               IA            19.73                48.06                 12.5 Gy × 4fx
  22               IB            47.98                90.31                 12.5 Gy × 4fx
  23               IA            9.04                 29.96                 12.5 Gy × 4fx
  24               IA            3.69                 11.33                 12.5 Gy × 4fx
  25               IB            30.24                52.15                 12.5 Gy × 4fx
  26               IA            2.95                 13.27                 12.5 Gy × 4fx
  27               IB            64.45                125.02                12.5 Gy × 4fx
  28               IA            8.24                 24.78                 12.5 Gy × 4fx
  29               IA            6.89                 22.65                 12.5 Gy × 4fx
  30               IA            17.22                40.32                 12.5 Gy × 4fx
  31               IA            20.15                53.47                 12.5 Gy × 4fx
  32               IB            56.43                98.56                 12.5 Gy × 4fx
  33               IA            8.67                 27.69                 12.5 Gy × 4fx
  34               IB            52.65                93.57                 12.5 Gy × 4fx
  35               IA            5.88                 22.65                 12.5 Gy × 4fx
  36               IB            62.86                119.68                12.5 Gy × 4fx
  37               IA            3.56                 10.74                 12.5 Gy × 4fx
  38               IA            12.62                36.66                 12.5 Gy × 4fx
  39               IB            36.88                80.98                 12.5Gy × 4fx
  40               IB            66.86                124.68                12.5 Gy × 4fx
  41               IB            49.89                96.68                 12.5 Gy × 4fx
  42               IA            4.89                 20.38                 12.5 Gy × 4fx
  43               IB            32.62                60.88                 12.5 Gy × 4fx
  44               IA            3.88                 12.28                 12.5 Gy × 4fx
  45               IB            46.66                88.62                 12.5 Gy × 4fx
  46               IA            6.84                 20.66                 12.5 Gy × 4fx
  47               IA            5.68                 21.28                 12.5 Gy × 4fx
  48               IA            16.56                42.66                 12.5 Gy × 4fx
  49               IA            12.42                32.86                 12.5 Gy × 4fx
  50               IB            58.88                102.68                12.5 Gy × 4fx
  Median (range)                 19.94 (0.92-70.82)   47.56 (5.87-133.20)    

Abbreviations: ITV, internal target volume; NSCLC, non-small cell lung cancer; PTV, planning target volume.

Treatment Planning {#section4-1533033820916505}
------------------

All patients data (Image sets, RtStructure) are imported into the RayStation (Ver.8B, Raysearch Labs, Sweden), and 2 types of SBRT plans, using PTV-based conventional optimization (CO-PTV) and RO-ITV, are regenerated using the same beam geometry as clinical SBRT plans in Raystation. However, the prescribed dose of all plans is directly delivered to the ITV, with each plan normalized such that 100% of the prescribed dose covered 95% of the ITV. Moreover, patient setup uncertainty is differently handled; while the RO-ITV plan using a robust optimization algorithm is based on ITV. As described by Fredriksson *et al* ^[@bibr12-1533033820916505][@bibr13-1533033820916505]-[@bibr14-1533033820916505]^, the robust optimization in RayStation is a minimax optimization. The minimax optimization method minimizes the objective function value such that the prescription dose is valid even in the worst-case scenario and with respect to setup uncertainties. In practice, over 95% of the ITV volume received prescription dose (*D* ~95%~ ≥ 5000 cGy) and 99% of the ITV volume received 90% of prescription dose (*D* ~99%~ ≥ 4500 cGy) are used in the robust function, in which patient setup uncertainties are taken into account by shifting the plan isocenter 5 mm in the LR direction, 5 mm in the inferior-superior direction, and 5 mm in the AP direction. Thus, the worst-case robust optimization took into account 6 setup uncertainties and generated SBRT plans by minimizing the penalty of the worst cases for the ITV. Another important point is that, in order to minimize dose spillage, auxiliary structures, such as 2 rings compassing the target area, should have lower dose limits compared with CO-PTV. This is due to the volume of the ITV, which is smaller than that of the PTV, and which results in steep gradient falloffs, away from the target edge.

The interfraction motion is generally more complex to model and is often modeled as a setup error.^[@bibr15-1533033820916505]^ A treatment plan, which only considers fixed setup errors, yields a dose distribution which is comparable to a CO-PTV. Actually, setup errors might be averaged over the course of treatment and most studies in the IMRT model the setup errors using Gaussian distributions in 3 dimensions. The integration of uncertainties, with setup errors into the optimization process, induces an automatic expansion of CTV that expect a dose, which covers enough target under uncertainties. Sir *et al* ^[@bibr16-1533033820916505]^ investigated in detail the setup errors of what the shape of the dose falloff, at the edge of the target volume, depends on.

Plan Quality Evaluation {#section5-1533033820916505}
-----------------------

Both RO-ITV and CO-PTV plans were normalized to have 5000 cGy at ITV of *D* ~95%~. The dosimetric parameters, including ITV dose coverage, conformity index (CI), homogeneity index (HI), DFP, and OARs are compared for RO-ITV and CO-PTV according to ICRU 0915.

The ITV dose coverage is described as 99% of the target volume (ITV) that received a minimum of 90% of the prescription dose (ITV: *V* ~90%RX~ ≥ 99%).

The $\text{CI}$ is calculated using Equation [1](#disp-formula1-1533033820916505){ref-type="disp-formula"}:
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Where VRI is the prescription isodose volume and TV the ITV volume.

The HI is calculated using Equation [2](#disp-formula2-1533033820916505){ref-type="disp-formula"}:
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Where *D* ~2%~, *D* ~98%~, and *D* ~50%~ are the doses that cover 2%, 98%, and 50% of the ITV, respectively. The DFP, defined as the product of *R* ~50%~ and *D*2cm, was found to have a weak relationship with tumor size and is therefore used to compare the intermediate-dose spillage of the SBRT plan.^[@bibr17-1533033820916505]^

DFP is expressed by Equation [3](#disp-formula3-1533033820916505){ref-type="disp-formula"}:
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Where *R* ~50%~ is the ratio of 50% of the prescription isodose volume to the ITV and *D*2cm is the maximum dose at 2 cm from the ITV in any direction.

The OARs are also evaluated using dose--volume histogram (DVH) metrics, such as lung (*D* ~mean~, *V* ~20~), spinal cord *D* ~1cc~ and NT (*V* ~50%RX~), where NT is a ring with body minus boundary that is away from ITV is 2 cm; *V* ~50%RX~ is NT volume received a minimum prescription dose of 50%.

Toxicity Assessment {#section6-1533033820916505}
-------------------

The dose--volume relationships for lung complications has been studied for several years in lung cancer. The popular Lman normal tissue complication (NTCP) model was used to fit the dose--volume relationship to the clinical data. However, there are large uncertainties in the NTCP model and its associated model parameters, which might reflect subjectivity in the scoring complications, disparity in end points, and dosimetric uncertainties. In current studies, the Lyman NTCP model in the Moiseenko studies^[@bibr18-1533033820916505]^ is used to assess the dependence of lung complications incidence on the dose--volume for both RO-ITV and CO-PTV plans. The parameters details are presented in [Table. 2](#table2-1533033820916505){ref-type="table"}. In the Moiseenko studies, long survival allowed the assessment of lung complications data in patients with thymoma for acute and late response, which make the model parameters best suited for their data.

###### 

Parameters Used in the Lyman-Kutcher-Burman Model.

![](10.1177_1533033820916505-table2)

  Parameter   Volume       D50, cGy   M      N     α/β, Gy
  ----------- ------------ ---------- ------ ----- ---------
  NTCP        Both lungs   2190       0.37   0.8   3

Abbreviation: NTCP, normal tissue complication probability.

Robustness Quantification {#section7-1533033820916505}
-------------------------

Although a patient setup uncertainty of 5 mm was introduced for both CO-PTV and RO-ITV in SBRT planning, it was necessary to study the situation in which the setup uncertainty is less than 5 mm in the evaluation of robustness, which could be caused by updating the IGRT equipment. Therefore, the evaluation of robustness in SBRT planning started with the creation of 3 scenarios or setup groups whose details are as follows:*3-mm setup group*: nominal scenario (no setup uncertainty) and 14 uncertainty scenarios (6 with 3 mm in X, Y, and Z directions, respectively; and 8 with 3 mm in diagonal directions) that simulate a 3-mm maximum setup isotropic space.*4-mm setup group*: nominal scenario (no setup uncertainty) and 14 uncertainty scenarios (6 with 4 mm in X, Y, and Z directions, respectively; and 8 with 4 mm in diagonal directions) that simulate a 4-mm maximum setup isotropic space.*5-mm setup group:* nominal scenario (no setup uncertainty) and 14 uncertainty scenarios (6 with 5 mm in X, Y, and Z directions, respectively; and 8 with 5 in diagonal directions) that simulate a 5-mm maximum setup isotropic space.

Hence, a total of 15 perturbed dose distributions were computed for each setup group. In the case of the ITV, the metrics included the DVHBW.

The DVHBW can be expressed by Equation [4](#disp-formula4-1533033820916505){ref-type="disp-formula"}:
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Where $D_{x}^{s}$ is the DVH metric of the ITV in*x* relative volume (%) for setup group $\ s$. In short, the DVHBW represents the variation of DVH metrics in a setup group. In our studies, the values of *x* are 95, 98, and 99, due to the sensitivity of the DVH metric, in the ITV coverage, to the setup uncertainty in the SBRT planning. A total of 3 DVHBWs were obtained in the ITV target (*D* ~95~, *D* ~98~, *D* ~99~) under 1 setup group, in which it was separately compared between the RO-ITV and CO-PTV plans. Furthermore, the mean DVHBW was calculated by averaging 3 DVHBWs for 1 group.

Another metric, the voxel-wise dose distribution (VWDD),^[@bibr19-1533033820916505]^ was introduced for plan robustness. The VWDD-min as an aggregate dose distribution based on the minimum dose value, in each voxel and over all scenarios, was used to evaluate the target coverage. The VWDD-max, which is an aggregate dose distribution based on the maximum dose value, in each voxel over all scenarios, was used to evaluate OAR sparing.

Statistical Analysis {#section8-1533033820916505}
--------------------

The student *t* test was carried out to compare the pairwise difference between 2 treatment techniques (CO-PTV and RO-ITV) in term of plan quality, risk of RP, and plan robustness. A *P* value \< .05 was considered statistically significant. A study was performed using a nonlinear model with Excel software version (v.2016, Microsoft; <https://www.microsoft.com>) to evaluate the correlation between the mean DVHBW and 3 setup groups.

Results {#section9-1533033820916505}
=======

Target Dose Coverage {#section10-1533033820916505}
--------------------

In general, RO-ITV met the ITV coverage and critical organ dose objectives according the Radiation Therapy Oncology Group (RTOG) 0915 were used for the SBRT plans.^[@bibr11-1533033820916505]^ In [Figure 1](#fig1-1533033820916505){ref-type="fig"}, more details are shown, comparing RO-ITV to CO-PTV.

![Plan quality comparison between RO-ITV and CO-PTV in *V* ~90%RX~, HI, CI, and DFP. CI indicates conformity index; CO-PTV, planning target volume-based conventional optimization; DFP, dose falloff product; HI, homogeneity index; RO-ITV, internal target volume-based robust optimization.](10.1177_1533033820916505-fig1){#fig1-1533033820916505}

The most important target coverage parameters, *V* ~90%RX~ and *V* ~100%RX~, are satisfied by both RO-ITV and CO-PTV plans, with no significant differences between them.An acceptable CI was defined as \<1.2 and \<1.5 for a deviation in RTOG 0915. The value of CI for RO-ITV was 1.17 for RO-ITV versus 1.27 for CO-PTV (*P* \< .001; for ITV).Although a HI was not required by RTOG 0915, we observed that the HI was 0.18 for RO-ITV versus 0.17 for CO-PTV (*P* \< .05).The falloff gradient beyond the ITV that extends into NT structures should be steep in all directions and meet *R* ~50%~ and *D*2cm according to RTOG 0915. The DFP, as an effective metric and regardless of tumor size, was investigated and found to be better in RO-ITV. For ITV, it was 129 for RO-ITV versus 167 for CO-PTV (*P* \< .001).

Organ at Risk and RP {#section11-1533033820916505}
--------------------

Many dosimetric OAR parameters were lower for RO-ITV compared to CO-PTV ([Figure 2](#fig2-1533033820916505){ref-type="fig"}). The mean dose in lung tissue (*D* ~mean~) was 415 cGy for RO-ITV compared to 451 cGy for CO-PTV (*P* \< .05) and the lung *V* ~20~ values were 5.4% for RO-ITV compared to 6.0% for CO-PTV (*P* \< .05). In addition, the 50% prescription isodose volume (*V* ~50%RX~) in the NT was significantly lower when irradiated with the RO-ITV plans (*P* \< .05).

![Plan quality comparison between RO-ITV and CO-PTV in lung (*D* ~mean~), lung (*V* ~20~), spinal cord (*D* ~1cc~), and NT (*V* ~50%RX~). CO-PTV indicates planning target volume-based conventional optimization; NT, normal tissue; RO-ITV, internal target volume-based robust optimization.](10.1177_1533033820916505-fig2){#fig2-1533033820916505}

The SBRT plan with the RO-ITV methods revealed significantly superior mean NTCP values for the lung (NTCP = 4.2%) compared to CO-PTV (NTCP = 5.5%; *P* \< .05; [Figure 3](#fig3-1533033820916505){ref-type="fig"}). Consequently, the RO-ITV demonstrated a lower risk of RP compared to the CO-PTV technique for the lung.

![NTCPs for lung in both RO-ITV and CO-PTV (The y-axis is a % probability). CO-PTV indicates planning target volume-based conventional optimization; NTCP, normal tissue complication probability; RO-ITV, internal target volume-based robust optimization.](10.1177_1533033820916505-fig3){#fig3-1533033820916505}

Robustness Analysis: DVHB {#section12-1533033820916505}
-------------------------

A 5-mm setup uncertainty may be an overestimate due to the updating of immobilization and image-guided devices during patient treatment delivery. Therefore, the effects of 3- and 4-mm setup uncertainties on the plan are also evaluated. [Figure 4A-C](#fig4-1533033820916505){ref-type="fig"} shows a comparison of the ITV-DVHBW using the DVH metric (*D* ~95~, *D* ~98~, *D* ~99~) under 3-, 4-, and 5- setup groups between the RO-ITV and CO-PTV plans and with average values for all directions. Further details include:

![The box plot depicting the statistical result of DVHBW $\left( {\Delta D} \right)$ for ITV in *D* ~99~, *D* ~98~, and *D* ~95~ between RO-ITV plan and CO-PTV plan under 3 setup uncertainties group. The center line inside the box is the median value and the cross line represents average value. Correlation analysis between mean DVHBW and setup uncertainties for CO-PTV plan (solid line) and RO-ITV plan (dot line). Results showed probability correlation between the average DVHBW and setup group. CO-PTV indicates planning target volume-based conventional optimization; DVHBW, dose--volume histogram band width; RO-ITV, internal target volume-based robust optimization.](10.1177_1533033820916505-fig4){#fig4-1533033820916505}

For the 3-mm setup group, it was observed that the mean DVHBW is smaller in RO-ITV: for ITV (*D* ~99~), it was 48 cGy for RO-ITV versus 80 cGy for CO-PTV (*P* \< .01); for ITV (*D* ~98~), it was 42 cGy for RO-ITV versus 78 cGy for CO-PTV (*P* \< .01); and for ITV (*D* ~95~), it was 38 cGy for RO-ITV versus 62 cGy for CO-PTV (*P* \< .01). On the other hand, the mean DVHBs were reduced from ITV (*D* ~99~) to ITV (*D* ~95~), due to the sensitivity of *D* ~99~ to the setup uncertainty compared to *D* ~95~.A narrow DVHBW for RO-ITV and a lower DVHB value for *D* ~95~ were also observed for the 4-mm setup and 5-mm setup groups (see [Figure 4B and C](#fig4-1533033820916505){ref-type="fig"} for specific average values). We also found that the average DVHBW in *D* ~95~, *D* ~98~, and *D* ~99~ increased from the 3-mm setup to the 5-mm setup group ([Figure 4D](#fig4-1533033820916505){ref-type="fig"}). The average DVHBW was 42 cGy for the RO-ITV plans compared to 73 cGy for the CO-PTV plans in the 3-mm setup group; 88 cGy for the RO-ITV plans compared to 176 cGy for the CO-PTV plans in the 4-mm setup group; 229 cGy for the RO-ITV plans to 490 cGy for the CO-PTV plans in the 5-mm setup group.A statistical correlation study was performed to evaluate the correlation between the average DVHBW and the setup group and showed the existence of an exponential relationship between the 2 ([Figure 4D](#fig4-1533033820916505){ref-type="fig"}). For RO-ITV, the expression was $\Delta D_{\text{RO-ITV}} = 2.8e^{1.03r}$; while for the CO-PTV plans, it was $\Delta D_{\text{CO-PTV}} = 1.6e^{0.9r}$, where $r\ $ is equal to 3, 4, and 5 mm. It was observed that the DVHBW in CO-PTV plans was much steeper than in RO-ITV plans, which indicated that while SBRT planning against setup uncertainties can be improved by robust optimization methods, this improvement decreases exponentially with increased setup uncertainty.

Voxel-Wise Dose Distribution {#section13-1533033820916505}
----------------------------

The VWDD-min/max are used in the transverse plane for a representative patient to illustrate the robustness of RO-ITV plans ([Figure 5](#fig5-1533033820916505){ref-type="fig"}, right panels) against setup uncertainty when compared with CO-PTV plans ([Figure 5](#fig5-1533033820916505){ref-type="fig"}, left panels). The 5000 and 4500 dose line covered a greater ITV volume in the RO-ITV plans, as determined by the VWDD-min ([Figure 5A and D](#fig5-1533033820916505){ref-type="fig"}). It was also observed that less volume was irradiated in the RO-ITV plans using the 2500 cGy dose line on the VWDD-max ([Figure 5B and E](#fig5-1533033820916505){ref-type="fig"}) for NT organ. In addition, RO-ITV plans provided better target coverage according to the ITV-DVH metric (*V* ~100%RX~) than the CO-PTV plans in the worst-case scenario (92.1% vs 82.3%) and are shown in [Figure 5C and F](#fig5-1533033820916505){ref-type="fig"}.

![Dose distributions in the transverse plane for a representative patient illustrate the insensitivity of RO-ITV plan (left panels) to set up uncertainties compared with the CO-PTV plan (right panels). The 5000 and 4500 cGy dose line covered a little more ITV volume in RO-ITV plans from Voxel-wise minimum dose distribution (A and D). It was observed that less volume was irradiated in RO-ITV plans according to 2500 and 2000 cGy on Voxel-wise maximum dose distribution (B and E) for NT organ. In addition, RO-ITV plans provided better target coverage in ITV-DVH metric (*V* ~100%RX~) than the CO-PTV plans in the worst scenario, as shown in C and F. CO-PTV indicates planning target volume-based conventional optimization; ITV, internal target volume; NT, normal tissue; RO-ITV, internal target volume-based robust optimization.](10.1177_1533033820916505-fig5){#fig5-1533033820916505}

Discussion {#section14-1533033820916505}
==========

The purpose of this study is to investigate the feasibility of SBRT planning using RO-ITV methods. To this end, we performed a comprehensive comparison between the RO-ITV and CO-PTV optimization methods based on plan quality and robustness for patients with early stage NSCLC. The goal of lungs SBRT is to deliver an ablative dose to a lung tumor while sparing as much of the surrounding NT as possible. According to the RTOG protocol, the falloff gradient beyond the target extending into NT structure must be steep in all directions.^[@bibr11-1533033820916505]^ In the present study, the RO-ITV demonstrated its great potential in maintaining target coverage, while reducing that of NT. The conformality of tumor coverage and intermediate-dose spillage was evidently lower in the RO-ITV plans, as shown in [Figure 1](#fig1-1533033820916505){ref-type="fig"}. Furthermore, we found that the RO-ITV method performed well in regions where the dose should have been minimal, such as the NT in [Figure 2](#fig2-1533033820916505){ref-type="fig"}.

Studies have shown that when the biological effective dose is above 100 Gy, the local control and survival significantly improve for patients with early stage NSCLC.^[@bibr1-1533033820916505]^ However, RP is a major form of toxicity that limits the increases in the fraction dose in SBRT for lung cancer. Numerous studies have reported that up to 29% SBRT-induced RP cases require clinical intervention.^[@bibr20-1533033820916505],[@bibr21-1533033820916505]^ Therefore, such high standards for SBRT have led to much tighter tolerances when treatment planning was performed, and much effort was expended to limit toxicity. Our results show that SBRT plans, using RO-ITV, achieve significant sparing of lung dose compared with the CO-PTV plans, as illustrated by the lung (*D* ~mean~, *V* ~20~) in [Figure 2](#fig2-1533033820916505){ref-type="fig"}. The probability of RP was also proved to be lower for RO-ITV ([Figure 3](#fig3-1533033820916505){ref-type="fig"}). A qualitative explanation of the results goes as follows: typically, the priority in treatment planning is to make sure that the ITV receives the prescribed dose despite uncertainty. In specific cases, especially when the OARs are very close to target and NTs, it is also important for target coverage. Stereotactic body radiotherapy for lung tumors is an example, where sparing of lung NT is relative important to target coverage. In this case, the ITV is expanded by a margin, with a probability distribution that considers setup uncertainty, which might be superior than the plan where ITV is expanded by a fixed margin. Therefore, ITV robust treatment planning creates a plan that easily meets the average dose to the lung.

For the treatment centers which update image-guided devices during treatment delivery, handling the 5-mm setup uncertainty according to the ICRU protocol may result in dose overestimates. It is therefore necessary to consider plan robustness under 3- and 4-mm setup uncertainties. In our studies, 3 groups of setup uncertainties were created to investigate plan robustness, while the proposed DVHBW method was used to provide a simple metric to cross-compare the robustness of SBRT plans based on the RO-ITV and CO-PTV methods. We selected the *D* ~99~, *D* ~98~, and *D* ~95~ ITV as indicators due to their sensitivity to the setup uncertainties. The ITV (*D* ~99~) is more sensitive than the ITV (*D* ~95~) due to the need of more voxels to account for setup uncertainties, while ITV ( *D* ~98~) served as a reference value. Three values of ITV target coverage would be able to reflect the robustness of the plan under setup uncertainties. From the result shown in [Figure 4A-C](#fig4-1533033820916505){ref-type="fig"}, the ITV-based optimization made the plan more robust against setup uncertainties. This can be explained by the algorithm used in robust optimization, which allows the planner to consider setup uncertainties before performing plan optimization. The robust optimization algorithm discretize setup uncertainties into multiple scenarios. The uncertainty in each scenario is taken into account by the objective function during plan optimization, such that the prescription holds true for each of the various setup uncertainties. An approximative exponential relationship exists between the mean DVHBW and the setup uncertainties, as illustrated in [Figure 4D](#fig4-1533033820916505){ref-type="fig"}. This relationship indicates that, no matter which optimization method is used, the target coverage will sharply deteriorate with an increased setup uncertainty but the deterioration is slower using RO-ITV plans.

In order to simplify the method of comparing plan robustness of the RO-ITV and CO-PTV plans, DVHBW is used in the target coverage. The approach is different from a root mean square dose (RMSD)-volume histograms (RVH) method,^[@bibr22-1533033820916505],[@bibr23-1533033820916505]^ which calculates the RMSD of the 15 doses (ie, 3-mm setup group: nominal scenario \[no setup uncertainty\] and 14 uncertainty scenarios \[6 with 3 mm in X, Y, and Z directions, respectively; and 8 with 3 mm in diagonal directions\]) for each voxel within a given structure. The area under the RVH curve in a structure gave a numerical index summarizing plan robustness similar to the way in which the equivalent uniform dose is summarized by a DVH. Thus, plan robustness could also be evaluated by comparing the area under the RVH for the ITV of the RO-ITV and CO-PTV plans. However, RVH is an approach that actually takes into account all the voxels within the ITV; whereas, certain voxels within ITV, for example, prescription isodose surface coverage, are more important in SBRT planning. Voxel wise min/max distribution, as a supplementary method to the DVHB metric, takes into account all the voxels within the patient's body, from which perturbations in the dose caused by setup uncertainties are distributed at the boundary of the target area ([Figure 5](#fig5-1533033820916505){ref-type="fig"}).

Our results provide compelling evidence for the RO-ITV plans, in which plan quality and robustness are obviously advantageous compared to the CO-PTV methods; however, some limitations are worth noting. We assumed that the CO-PTV plan was optimized to PTV coverage of the prescribed dose and then normalized to ITV 95% coverage. This may cause a down normalization of the final CO-PTV with the cost function not being the best design for it. For robust optimized plans, with normalized to 95% coverage of ITV, the cost function may a better fit. Therefore, the compromise method is to normalize the plan to ITV 99% coverage. Due to this normalization that makes RO-ITV plan up and CO-PTV plan slightly down, we picked up 2 extreme cases from the patient's cohort to verify the conclusion. [Figure 6](#fig6-1533033820916505){ref-type="fig"} shows the results in both plan quality (patient no. 12) and robustness (patient no. 14) with the dosimetric details shown in [Table 3](#table3-1533033820916505){ref-type="table"}. Our results show that the conclusion is still valid when normalizing the plan to ITV 99% coverage for the CO-PTV and RO-ITV plans.

![Plan quality comparison (patient no. 12) and plan robustness comparison (patient no. 14) with normalization the plan to 99% coverage of ITV. ITV indicates internal target volume.](10.1177_1533033820916505-fig6){#fig6-1533033820916505}

###### 

Plan Quality and Robustness Comparison for 2 Representative Patients.

![](10.1177_1533033820916505-table3)

                                 Patient No. 12   Patient No. 14          
  ------------------------------ ---------------- ---------------- ------ ------
  CI                             1.08             1.12             1.34   1.47
  HI                             0.18             0.17             0.31   0.26
  DFP                            143              157              288    369
  Lung (*D* ~mean~, cGy)         325              340              684    787
  Lung (*V* ~20~, %)             2.17             2.26             8.73   9.65
  Spinal cord (*D* ~1cc~, cGy)   203              398              560    628
  NT                             0.3              0.4              1.46   1.98
  NTCP, %                        3.1              3.2              4.83   5.46
  DVHBW, cGy                     192              302              166    329

Abbreviations: CI, conformity index; CO-PTV, planning target volume-based conventional optimization; DFP, dose falloff product; DVHBW, dose--volume histogram band width; HI, homogeneity index; NT, normal tissue; NTCP, normal tissue complication probability.

Another limit is associated with the intrafractional motion issue in treatment of NSCLC-SBRT, which may cause considerable changes in the relative position of the tumor geometry and the MLC aperture, which subsequently has an impact on the dose distribution of the target and the risk to surrounding organs. This is the interplay effect, which had been reported to degrade the quality of the dose delivery.^[@bibr24-1533033820916505],[@bibr25-1533033820916505]^ Notably, we did not attempt to consider issues associated with intrafractional motion, although this might be desirable since a similar issue is present in the GTV-to-ITV margin for the ITV-based plan. One group has proposed the use of the difference between the 4D accumulated dose (4DD) and the 4D dynamic accumulated dose (4DDD) to evaluate interplay effects on the treatment plan.^[@bibr26-1533033820916505],[@bibr27-1533033820916505]^ The 4DD is a static dose that averages the sum of the doses calculated during the 10 individual phases of a 4DCT image without considering time dependence in the treatment delivery. The 4DDD is a dynamic dose that considers time dependence in the treatment delivery, together with changes in anatomy, owing to respiratory motion. Studies have shown that the 4DDD converges to the 4DD, indicating that its random nature allows the effect of interplay to be averaged out after multiple fractions.^[@bibr28-1533033820916505]^ Many studies^[@bibr29-1533033820916505],[@bibr30-1533033820916505]^ have also shown that the interplay effect does not significantly affect the cumulative dose distribution over multiple fractions. Besides interplay effects, the erratic motion of target on the treatment day that is not captured on the CT simulation is also not considered here, for example, when a patient coughs or breathes deeply on the linac but not on the CT simulation, the error could be larger in RO-ITV based approach.

5. Conclusions {#section15-1533033820916505}
==============

Robust optimization plans provided a better quality plan for target coverage and OAR and for a lower RP according to the lung Lyman-Kutcher-Burman NTCP model. The plan robustness is also shown to be better under different kinds of setup uncertainty scenarios. A novel strategy is introduced to quantitatively evaluate robustness plan using the DVHBW. Our studies show that DVHBW in RO-ITV is significantly lower, which makes the SBRT plan more robust against setup uncertainties. Furthermore, while target coverage sharply deteriorates (approximately exponentially) with increased setup uncertainty, the coverage with RO-ITV is likely to be better than that with CO-ITV.
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AP

:   anterior--posterior

CI

:   conformity index

CO-PTV

:   PTV-based conventional optimization

CT

:   computed tomography

CTV

:   clinical target volume

DFP

:   dose falloff product

*D*~mean~

:   mean dose

DVH

:   dose--volume histogram

DVHBW

:   dose--volume histogram band width

GTV

:   Gross target volume

HI

:   homogeneity index

ICRU

:   International Commission Radiological Units

IGRT

:   image-guided radiation therapy

IMRT

:   intensity modulated radiotherapy

ITV

:   internal target volume

LR

:   left--right

MLC

:   multileaf collimation

NSCLC

:   non-small cell lung cancer

NT

:   normal tissue

NTCP

:   normal tissue complication probability

OAR

:   organ at risk

PTV

:   planning target volume

RMSD

:   root mean square dose

RO-ITV

:   ITV-based robust optimization

RP

:   radiation pneumonitis

RTOG

:   Radiation Therapy Oncology Group

RVH

:   RMSD volume histogram

SBRT

:   stereotactic body radiation therapy

t4Dplan

:   4-dimensional planning method

VWDD

:   voxel-wise dose distribution

4-D

:   4-dimensional

4DCT

:   4-dimensional computed tomography

4DD

:   4D accumulated dose

4DDD

:   4D dynamic accumulated dose
